LAVA Therapeutics NV (LVTX)

Evaluation: Based on all recent filings, financial statements, and news.

See full evaluation
Ask a question about LAVA Therapeutics NV (LVTX)
Company Performance

Current Price

as of Oct 16, 2024

$1.65

P/E Ratio

N/A

Market Cap

$43.38M

Description

LAVA Therapeutics NV is an immuno-oncology company, which engages in the proprietary Gammabody platform to develop a portfolio of bispecific gamma delta T cell engagers for the potential treatment of solid tumors and hematological malignancies. The company was founded by Erik van den Berg in 2016 and is headquartered in Utrecht, the Netherlands.

Metrics

Overview

  • HQUtrecht, NB
  • SectorHealth Technology
  • IndustryBiotechnology
  • TickerLVTX
  • Price$1.65+3.12%

Trading Information

  • Market Cap$43.38M
  • Float53.88%
  • Average Daily Volume (1m)32,724
  • Average Daily Volume (3m)45,940
  • EPS-$0.91

Company

  • Revenue$7.40M
  • Rev Growth (1yr)-100.00%
  • Net Income-$8.30M
  • Gross MarginN/A
  • EBITDA MarginN/A
  • EBITDA-$9.13M
  • EV-$32.36M
  • EV/Revenue-4.37
  • P/EN/A
  • P/S5.98
  • P/B1.01
Documents